Literature DB >> 26934353

[Genetic information from tumor-infiltrating B lymphocytes as a driver tool ("GPS") for anti-tumor T cell CARs].

Beatrix Kotlan1, Orsolya Csuka2, László Tóth3, Emil Farkas3, Vanda Plótár4, Szabolcs Horváth4, Klára Éles4, Judit Olasz2, József Tóth4, Miklós Kásler5, Gabriella Liszkay6.   

Abstract

The rapidly growing field of gene therapy techniques to modify T cells with chimeric antigen receptors (CARs) for cancer care solutions, reached considerable achievements. However, there is an urgent need of reliable, well tolerable tumor-associated antigen specific antibodies. Tumor-infiltrating B (TIL-B) cell originated single chain Fv (scFv) gene regions could be selected with tumor specificity. DNA sequences of these antibody variable regions were subjects to get engineered into new CAR constructs. Our novel strategy harnesses tumor-infiltrating B cells' unique capacity to reveal highly tumor-associated disialylated glycosphingolipids (GD3 gangliosides). We used these human antibody fragments for generating GD3 ganglioside specific CAR gene constructs for potential usage in solid tumors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26934353

Source DB:  PubMed          Journal:  Magy Onkol        ISSN: 0025-0244


  2 in total

1.  Challenging tumour immunological techniques that help to track cancer stem cells in malignant melanomas and other solid tumours.

Authors:  Beatrix Kotlan; Vanda Plotar; Klara Eles; Szabolcs Horvath; Timea Balatoni; Orsolya Csuka; Mihaly Újhelyi; Ákos Sávolt; Andras Szollar; Istvan Vamosi-Nagy; Laszlo Toth; Emil Farkas; Jozsef Toth; Miklos Kasler; Gabriella Liszkay
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

2.  Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.

Authors:  Beatrix Kotlan; Szabolcs Horvath; Klara Eles; Vanda K Plotar; Gyorgy Naszados; Katalin Czirbesz; Miri Blank; Emil Farkas; Laszlo Toth; Jozsef Tovari; Andras Szekacs; Yehuda Shoenfeld; Maria Godeny; Miklos Kasler; Gabriella Liszkay
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.